We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
Read MoreHide Full Article
Key Takeaways
Dyne launched the phase III FORZETTO for z-rostudirsen in DMD patients amenable to exon 51 skipping.
DYN's FORZETTO study will assess muscle and respiratory function over 73 weeks in 90 patients.
Z-rostudirsen showed improved motor function in DELIVER and may support a planned U.S. BLA filing.
Shares of Dyne Therapeutics (DYN - Free Report) rose 10% on Wednesday after the company announced the initiation of the phase III FORZETTO study evaluating the safety and efficacy of zeleciment rostudirsen (z-rostudirsen/DYNE-251) in ambulatory male patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
DMD is a rare, progressive neuromuscular disorder caused by mutations in the DMD gene that lead to little or no production of dystrophin, a protein essential for muscle function. The disease usually begins in early childhood with muscle weakness and gradually worsens over time, impacting mobility and overall physical function.
Year to date, shares of DYN have declined 10.3% compared with the industry’s 8.6% fall.
Image Source: Zacks Investment Research
Key Details of DYN’s Phase III FORZETTO Study
The phase III FORZETTO study aims to enroll around 90 participants aged four to 18 years, who will receive either z-rostudirsen or a placebo every four weeks. The primary endpoint is the change from baseline in rise from floor (RFF) velocity at week 73, a key measure of muscle strength and motor function in DMD. Secondary endpoints include several measures of motor and respiratory function, along with patient-reported outcomes.
More on DYN’s Z-rostudirsen
Previously, in the registrational expansion cohort of the phase I/II DELIVER study, treatment with z-rostudirsen demonstrated clinically meaningful improvements in RFF velocity versus placebo at six months, with a favorable safety profile. The study met its primary endpoint.
The data are expected to support a planned biologics license application seeking potential accelerated approval in the United States. Z-rostudirsen is being evaluated in the ongoing long-term extension phase of the DELIVER study.
Per management, Dyne has reached an agreement with the FDA on the design and protocol of the FORZETTO study, which is intended to serve as the confirmatory study supporting potential conversion of accelerated approval to full approval in the United States, as well as future regulatory filings in international markets.
Z-rostudirsen received several regulatory designations, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug status from global health authorities.
Besides z-rostudirsen, Dyne is advancing additional preclinical DMD programs such as DYNE-253, DYNE-245, DYNE-244 and DYNE-255 targeting multiple exon-skipping mutations in DMD.
Over the past 60 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. Over the same period, estimates for 2027 have improved from a loss of 39 cents to earnings of 11 cents per share. IMCR shares have lost 14.9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.10 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.47. INDV shares have risen 4.8% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 79.1% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
Key Takeaways
Shares of Dyne Therapeutics (DYN - Free Report) rose 10% on Wednesday after the company announced the initiation of the phase III FORZETTO study evaluating the safety and efficacy of zeleciment rostudirsen (z-rostudirsen/DYNE-251) in ambulatory male patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
DMD is a rare, progressive neuromuscular disorder caused by mutations in the DMD gene that lead to little or no production of dystrophin, a protein essential for muscle function. The disease usually begins in early childhood with muscle weakness and gradually worsens over time, impacting mobility and overall physical function.
Year to date, shares of DYN have declined 10.3% compared with the industry’s 8.6% fall.
Image Source: Zacks Investment Research
Key Details of DYN’s Phase III FORZETTO Study
The phase III FORZETTO study aims to enroll around 90 participants aged four to 18 years, who will receive either z-rostudirsen or a placebo every four weeks. The primary endpoint is the change from baseline in rise from floor (RFF) velocity at week 73, a key measure of muscle strength and motor function in DMD. Secondary endpoints include several measures of motor and respiratory function, along with patient-reported outcomes.
More on DYN’s Z-rostudirsen
Previously, in the registrational expansion cohort of the phase I/II DELIVER study, treatment with z-rostudirsen demonstrated clinically meaningful improvements in RFF velocity versus placebo at six months, with a favorable safety profile. The study met its primary endpoint.
The data are expected to support a planned biologics license application seeking potential accelerated approval in the United States. Z-rostudirsen is being evaluated in the ongoing long-term extension phase of the DELIVER study.
Per management, Dyne has reached an agreement with the FDA on the design and protocol of the FORZETTO study, which is intended to serve as the confirmatory study supporting potential conversion of accelerated approval to full approval in the United States, as well as future regulatory filings in international markets.
Z-rostudirsen received several regulatory designations, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease and Orphan Drug status from global health authorities.
Besides z-rostudirsen, Dyne is advancing additional preclinical DMD programs such as DYNE-253, DYNE-245, DYNE-244 and DYNE-255 targeting multiple exon-skipping mutations in DMD.
DYN’s Zacks Rank & Stocks to Consider
Dyne currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) , Indivior Pharmaceuticals (INDV - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. Over the same period, estimates for 2027 have improved from a loss of 39 cents to earnings of 11 cents per share. IMCR shares have lost 14.9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.10 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.47. INDV shares have risen 4.8% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 79.1% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.